REVEAL part A
65 evidence topics · 23 sources
Objective
Objectives of the pooled REVEAL Part A analysis
Adolescent and adult trial (NCT05606614 Part A): registered objective
Pediatric trial (NCT06152237): registered objective
Location and study date
Adolescent and adult trial (NCT05606614): registry dates
| Milestone | Registry record |
|---|---|
| Study start (actual) | “2023-03-06” |
| Primary completion (estimated) | “2031-06” |
| Study completion (estimated) | “2031-06” |
| Last update posted | “2026-07-07” |
Adolescent and adult trial (NCT05606614): registered sites for Parts A and B
| Country | Registry record |
|---|---|
| United States | “City of Hope” |
| United States | “UC San Diego” |
| United States | “UC San Francisco Benioff Children's Hospital” |
| United States | “Rush University Medical Center” |
| United States | “Kennedy Krieger Institute” |
| United States | “Boston Children's Hospital” |
| United States | “Washington University, St. Louis” |
| United States | “UT Southwestern Children's Medical Center” |
| Canada | “CHU St. Justine” |
Pediatric trial (NCT06152237): registry dates
| Milestone | Registry record |
|---|---|
| Study start (actual) | “2023-12-12” |
| Primary completion (estimated) | “2028-11-02” |
| Study completion (estimated) | “2031-11-02” |
| Last update posted | “2025-10-15” |
Pediatric trial (NCT06152237): registered sites
| Country | Registry record |
|---|---|
| United States | “Rush University Medical Center & Children's Hospital” |
| United States | “Gillette Children's Specialty Healthcare” |
| United States | “Washington University, St. Louis” |
| Canada | “CHU Ste-Justine” |
| United Kingdom | “Children's Neurosciences, Evelina London Children's Hospital, Guy's and St Thomas' NHS Foundation Trust” |
First adult participant dosed in Canada, June 2023
First pediatric participant dosed in the United States, January 2024, and United Kingdom authorization
Expansion of the adolescent and adult trial into the United States, February 2024
Completion of Part A dosing and data cutoffs
Study design
Pooled design as reported with the 12-month results
Two first-in-human trials described together as Part A
Adolescent and adult trial (NCT05606614): registered design elements
| Design element | Registry record |
|---|---|
| Phase (record now covers Parts A and B) | “Phase 3” |
| Allocation | “Non-Randomized” |
| Intervention model | “Sequential Assignment” |
| Masking | “Single (Outcomes Assessor)” |
| Masking description | “Central raters assessing the gain or regain of a developmental milestone from videos are blinded to the timing of each video.” |
| Follow-up | “Each participant will be followed for the observation period of 5 years after TSHA-102 administration in Part A and B.” |
Pediatric trial (NCT06152237): registered design elements
| Design element | Registry record |
|---|---|
| Allocation | “Randomized” |
| Intervention model | “Sequential Assignment” |
| Masking | “None (Open Label)” |
| Study duration | “The study duration is up to 6 years.” |
Dose-escalation rules with Independent Data Monitoring Committee review (pediatric protocol design)
Independent Data Monitoring Committee approval of dose escalation
Part B design as planned before the pivotal trial replaced it
Eligibility criteria
Adolescent and adult trial (NCT05606614): registered criteria
Adolescent and adult trial: eligibility extended from adults to age 12 and older, November 2023
Pediatric trial (NCT06152237): registered criteria
Treatment
Registered dose levels (adolescent and adult trial)
Dose cohorts pooled across both trials
Immunosuppression and intrathecal administration
Immunosuppression taper timing in the first two adult participants
Low dose as stated before the first participant was dosed
Comparability of Part A clinical material with the commercial process
Study outcomes
Rationale for using treatment-emergent adverse events as the primary endpoint
Registered primary outcome: adolescent and adult trial
Registered primary and exploratory outcomes: pediatric trial
Safety as the first objective of a first-in-human dose escalation
Developmental milestone gain or regain as the primary evidence of efficacy
Supplemental efficacy scales: MSEL-A, ORCA, and R-MBA
Statistical analysis description
Number of participants (Planned and analyzed)
Planned enrollment per trial
Enrollment recorded in the registries
| Field | Registry record |
|---|---|
| Enrollment (actual) | “6” |
Accrual over time
Participants analyzed at the May 2026 data cutoff
Description of analysis sets
Analysis set and data cutoff for the 12-month results
Natural history comparator sample sizes for R-MBA
| Time point | TSHA-102 | Natural history |
|---|---|---|
| 6 months | “TSHA-102 (N=12) SD=10.18” | “Natural History (N=75) SD= 5.97” |
| 12 months | “TSHA-102 (N=12) SD=8.86” | “Natural History (N=196) SD= 5.73” |
Planned analysis relative to each participant's baseline (pediatric protocol design)
Earlier analyses drawn from the electronic data capture system
Results
Participant disposition
All 12 participants followed for at least 12 months
Participants with data beyond 12 months
Baseline characteristics
Age, severity, and genotype of the 12 participants
Individual participants: age at dosing, baseline CGI-S, and follow-up
| Cohort and participant | Age at dosing (years) | Baseline CGI-S score | Post-treatment follow-up (months) |
|---|---|---|---|
| Low dose, participant 1 | “20” | “6” | “30” |
| Low dose, participant 2 | “21” | “4” | “30” |
| Low dose, participant 3 | “6” | “5” | “24” |
| Low dose, participant 4 | “7” | “4” | “24” |
| High dose, participant 1 | “15” | “5” | “18” |
| High dose, participant 2 | “21” | “5” | “18” |
| High dose, participant 3 | “8” | “5” | “18” |
| High dose, participant 4 | “15” | “5” | “12” |
| High dose, participant 5 | “16” | “5” | “12” |
| High dose, participant 6 | “6” | “4” | “12” |
| High dose, participant 7 | “7” | “6” | “12” |
| High dose, participant 8 | “6” | “5” | “12” |
First two adult participants: stage four disease
“20-year-old female at the time of dosing” (opens the source at this quote in a new tab)
“21-year-old female at the time of dosing” (opens the source at this quote in a new tab)
“Large MECP2 deletion affecting exons 3 and 4” (opens the source at this quote in a new tab)
“Missense MECP2 mutation (R133C)” (opens the source at this quote in a new tab)
First two pediatric participants: stage three disease
“6-year-old female at the time of dosing” (opens the source at this quote in a new tab)
“7-year-old female at the time of dosing” (opens the source at this quote in a new tab)
“Nonsense MECP2 mutation (R255X)” (opens the source at this quote in a new tab)
“Missense MECP2 mutation (R306C)” (opens the source at this quote in a new tab)
Efficacy results
Responses at 6, 12, and at least 18 months (May 2026 data cutoff)
| Endpoint | 6 months (N=12) | 12 months (N=12) | 18 months or more (N=7) |
|---|---|---|---|
| Participants who gained or regained at least one developmental milestone | “83%” | “100%” | “100%” |
| Average functional gains per participant | “22” | “23” | “26” |
| R-MBA mean score change versus natural history | “-11.0 P = 0.0011” | “-10.3 P = 0.0002” | “-11.0 P = 0.0046” |
| Participants with CGI-I score of 3 or less at multiple post-treatment assessments | “100%” | “100%” | “100%” |
| Participants with CGI-S total score improvement | “25%” | “25%” | “57%” |
Number of developmental milestones and additional skills
R-MBA mean change from baseline versus natural history, by dose
| Time point | TSHA-102 mean change | Natural history mean change | P value |
|---|---|---|---|
| 6 months | “-11.0” | “-0.81” | “P = 0.0011” |
| 12 months | “-10.3” | “-0.62” | “P = 0.0002” |
Dose comparison at the May 2025 data cutoff (10 participants)
| Endpoint | Low-dose cohort | High-dose cohort |
|---|---|---|
| Developmental milestone responder rate at 6 months | “75%” | “83%” |
| R-MBA mean score improvement at 6 months | “-9.8” | “-12.2” |
| R-MBA mean score improvement at 9 months or more | “-11.5” | “-18.0” |
| Mean CGI-I score at 6 months | “2.3” | “2.0” |
| Mean CGI-I score at 9 months or more | “2.8” | “1.0” |
| Participants with CGI-S improvement at latest visit | “25%” | “33%” |
Supplemental analysis at the May 2025 data cutoff
Health-related quality of life and patient-reported outcomes
Caregiver-reported communication (ORCA)
Caregiver global impression (PGI-I) in the first adult participants
Caregiver-reported behavior questionnaire (RSBQ)
Health-related quality of life instrument results
No evidence found.
Safety results
Treatment-emergent adverse events across the 12 participants (May 2026 data cutoff)
Most common treatment-related events, severity, and seizures
Transaminase pattern and other events at the May 2025 data cutoff
Events in the first four low-dose participants, including immunosuppression-related events
Safety across Part A, the pivotal trial, and ASPIRE (November 2026 data cutoff)
Study limitations
Summary
- Pooled sample: REVEAL Part A combines two separately registered phase 1/2 dose-escalation trials, NCT05606614 Part A (females aged 12 to <22 years) and NCT06152237 (females aged 5 to 8 years), into one analysis of 12 participants, 4 at the low dose and 8 at the high dose. Comparisons between doses rest on groups of 4 and 8 participants, and comparisons between age groups on 6 pediatric and 6 adolescent or adult participants.
- No concurrent control: Part A of both trials is open label, and the 2026 poster describes each participant as their own control. Efficacy is judged against each participant's baseline and against external data from the Rett syndrome Natural History Study. The R-MBA comparison draws on natural history samples of 75 participants at 6 months and 196 at 12 months, with MBA scores converted to R-MBA.
- Efficacy endpoints outside the registered Part A outcomes: the registered primary outcome of Part A in both trials is the proportion or incidence of participants with treatment-emergent adverse events and serious adverse events. Developmental milestone gain or regain, the primary evidence of efficacy in the 2026 poster, is registered as the primary outcome of Part B, and the poster describes evaluation criteria applied to available video-evidenced milestone data. The counts of additional skills derived from the MSEL-A, ORCA, and R-MBA come from a supplemental analysis, with ORCA data for 8 and MSEL-A data for 7 of the 12 participants; an earlier company announcement reported 165 additional skills or improvements across 10 participants from the same scales.
- Masking: the pediatric trial is registered with no masking. In the adolescent and adult trial, only the central raters of milestone videos are masked, and only to the timing of each video. The R-MBA is a clinician-reported evaluation and ORCA a caregiver-reported evaluation, collected in open-label trials.
- Follow-up: all 12 participants had at least 12 months of follow-up (range 12 to 30 months), and results at 18 months or more rest on 7 participants.
- Concomitant immunosuppression: prednisolone and sirolimus begin 7 days before dosing and are tapered over the following months. In the company's 2024 first-cohort data presentation, the most common event, vomiting, was described as a known risk of sirolimus, and eight nonserious events were attributed to immunosuppression.
- Heterogeneous population: participants were 6 to 21 years of age at dosing, had baseline CGI-S scores of 4 to 6, and carried varied MECP2 mutations; the pediatric trial was opened to stage three Rett syndrome and the adolescent and adult trial to stage four Rett syndrome.
- Sponsor reporting: all results come from Taysha press releases, SEC filings, presentations, and congress posters, and the 2025 poster states that its data came from the electronic data capture system and were subject to change.
- Inconsistencies between documents: the low dose was stated as 5x10^14 vg in June 2023 and as 5.7x10^14 vg in the registry and the third quarter 2026 Form 10-Q. The third quarter 2026 Form 10-Q describes both trials as randomized and NCT06152237 lists randomized allocation, while NCT05606614 lists non-randomized allocation, the 2023 pediatric design poster describes Part A as a single-arm dose escalation, and the 2024 first-cohort presentation plans randomization in Part B. The 2024 announcements planned at least 3 participants per dose in the pediatric trial and 3 high-dose participants in the adolescent and adult trial; NCT05606614 enrolled 2 low-dose and 4 high-dose participants, and the 12 Part A participants comprised 4 low-dose and 8 high-dose participants.